Aventum Partners acted as an adviser to Aho Group and Minerva Foundation and other selling shareholders on the sale of Yhtyneet Medix Laboratoriot (YML).
YML is the leading privately held clinical laboratory company in Finland offering comprehensive central laboratory services in the fields of clinical chemistry, clinical microbiology, pathology and genetics as well as in therapeutic drug testing, drugs of abuse testing and doping control in sports. In addition to 3 million laboratory tests carried out annually in its central laboratory, YML also covers web-based infectious disease home testing services, point-of-care testing in local laboratories and specimen collection services at customer locations. With approximately 150 employees, YML generated revenues exceeding EUR 15 million in 2017.
Aventum was retained to contact a limited number of synergistic and/or strategic trade buyer candidates on a confidential basis as the ownership was considered non-core to both majority owners, Aho Group and Minerva Foundation. Aventum initiated the project late in 2017 and took role in preparing sale material together with the management as well as leading the sale process to a successful deal.
After the competitive limited trade sale process managed by Aventum, the entire share capital of YML was sold to SYNLAB Group, the leading medical diagnostic services provider in Europe in July 2018, for an undisclosed value. The acquisition of YML strengthened Synlab’s market position in Finland while the largest and the second largest private medical central laboratory provider joined forces under Synlab’s ownership.
For further information regarding the transaction contact:
Olli Klemola, Managing Partner
olli.klemola@aventum.fi
+358 40 555 5614
